Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA.
Vermeirssen V, Deleu J, Morlion A, Everaert C, De Wilde J, Anckaert J, Durinck K, Nuytens J, Rishfi M, Speleman F, Van Droogenbroeck H, Verniers K, Baietti MF, Albersen M, Leucci E, Post E, Best MG, Van Maerken T, De Wilde B, Vandesompele J, Decock A. Vermeirssen V, et al. Among authors: van maerken t. NAR Cancer. 2022 Nov 28;4(4):zcac037. doi: 10.1093/narcan/zcac037. eCollection 2022 Dec. NAR Cancer. 2022. PMID: 36451702 Free PMC article.
Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
Van Maerken T, Speleman F, Vermeulen J, Lambertz I, De Clercq S, De Smet E, Yigit N, Coppens V, Philippé J, De Paepe A, Marine JC, Vandesompele J. Van Maerken T, et al. Cancer Res. 2006 Oct 1;66(19):9646-55. doi: 10.1158/0008-5472.CAN-06-0792. Cancer Res. 2006. PMID: 17018622
Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J Jr, Cuvelier CA, Marine JC, De Paepe A, Bracke M, Speleman F, Vandesompele J. Van Maerken T, et al. J Natl Cancer Inst. 2009 Nov 18;101(22):1562-74. doi: 10.1093/jnci/djp355. Epub 2009 Nov 10. J Natl Cancer Inst. 2009. PMID: 19903807
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, Vermeulen J, Van Roy N, Beiske K, Renard M, Noguera R, Delattre O, Janoueix-Lerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron H, Eggert A, Cools J, Versteeg R, Speleman F. De Brouwer S, et al. Among authors: van maerken t, van roy n, van den broecke c. Clin Cancer Res. 2010 Sep 1;16(17):4353-62. doi: 10.1158/1078-0432.CCR-09-2660. Epub 2010 Aug 18. Clin Cancer Res. 2010. PMID: 20719933
Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.
Kumps C, Fieuw A, Mestdagh P, Menten B, Lefever S, Pattyn F, De Brouwer S, Sante T, Schulte JH, Schramm A, Van Roy N, Van Maerken T, Noguera R, Combaret V, Devalck C, Westermann F, Laureys G, Eggert A, Vandesompele J, De Preter K, Speleman F. Kumps C, et al. Among authors: van maerken t, van roy n. PLoS One. 2013;8(1):e52321. doi: 10.1371/journal.pone.0052321. Epub 2013 Jan 4. PLoS One. 2013. PMID: 23308108 Free PMC article.
Effective Alu repeat based RT-Qpcr normalization in cancer cell perturbation experiments.
Rihani A, Van Maerken T, Pattyn F, Van Peer G, Beckers A, De Brouwer S, Kumps C, Mets E, Van der Meulen J, Rondou P, Leonelli C, Mestdagh P, Speleman F, Vandesompele J. Rihani A, et al. Among authors: van der meulen j, van maerken t, van peer g. PLoS One. 2013 Aug 14;8(8):e71776. doi: 10.1371/journal.pone.0071776. eCollection 2013. PLoS One. 2013. PMID: 23977142 Free PMC article.
57 results